FDA seeks to encourage more research on cannabis compounds' health effects | Zendy

Enos Gary | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

FDA seeks to encourage more research on cannabis compounds' health effects

Author(s) -

Enos Gary

Publication year - 2020

Publication title -

alcoholism and drug abuse weekly

Language(s) - English

Resource type - Journals

eISSN - 1556-7591

pISSN - 1042-1394

DOI - 10.1002/adaw.32792

Subject(s) - cannabis , food and drug administration , legislature , political science , business , public relations , medicine , psychology , pharmacology , psychiatry , law

Although federal legislative changes in recent years have created new opportunities for cannabis‐related clinical research, it remains unclear as to when — or even if — more drugs containing cannabis or cannabis‐derived compounds will eventually make it through the federal approval process. The Food and Drug Administration (FDA) on July 21 issued a draft guidance document for industry on cannabis‐related research, outlining a complexity of considerations that signal a challenging process for the research community.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research